High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study

References

• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.12815.
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. "Real-life" effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi:10.1016/j.jaip.2017.02.002.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Inoue H, Iwata T, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113(4):470–5e2. doi:10.1016/j.anai.2014.06.004.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC.
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosen K, Chipps BE, Luskin AT, Solari PG. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169 e2. doi:10.1016/j.jaci.2016.08.054.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, Ito R, Hashimoto S, Izuhara K, Suzukawa M, Ohta K, Ono J, Ohta S, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71(10):1472–1479. doi:10.1111/all.12922.
   PubMed Web of Science ®Google Scholar
• Raundhal M, Morse C, Khare A, Oriss TB, Milosevic J, Trudeau J, Huff R, Pilewski J, Holguin F, Kolls J, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125(8):3037–3050. doi:10.1172/JCI80911.
   PubMed Web of Science ®Google Scholar
• Modena BD, Bleecker ER, Busse WW, Erzurum SC, Gaston BM, Jarjour NN, Meyers DA, Milosevic J, Tedrow JR, Wu W, et al. Gene expression correlated with severe asthma characteristics reveals heterogeneous mechanisms of severe disease. Am J Respir Crit Care Med. 2017;195(11):1449–1463. doi:10.1164/rccm.201607-1407OC.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, Sousa A, Corfield J, Djukanovic R, Lutter R, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49(2):1602135. doi:10.1183/13993003.02135-2016.
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–1187. doi:10.1016/j.jaci.2009.02.024.
   PubMed Web of Science ®Google Scholar
• Mishra V, Banga J, Silveyra P. Oxidative stress and cellular pathways of asthma and inflammation: therapeutic strategies and pharmacological targets. Pharmacol Ther. 2018;181:169–182. doi:10.1016/j.pharmthera.2017.08.011.
   PubMed Web of Science ®Google Scholar
• Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, Matucci A, Macchia L, Vianello A, Vultaggio A, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–129. doi:10.1016/j.pupt.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med. 2018;52:78–85. doi:10.1016/j.ejim.2018.01.026.
   PubMed Web of Science ®Google Scholar
• Harada M, Obara K, Hirota T, Yoshimoto T, Hitomi Y, Sakashita M, Doi S, Miyatake A, Fujita K, Enomoto T, et al. A functional polymorphism in IL-18 is associated with severity of bronchial asthma. Am J Respir Crit Care Med. 2009;180(11):1048–1055. doi:10.1164/rccm.200905-0652OC.
   PubMed Web of Science ®Google Scholar
• Patil SP, Wisnivesky JP, Busse PJ, Halm EA, Li XM. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann Allergy Asthma Immunol. 2011;106(3):205–213. doi:10.1016/j.anai.2010.11.019.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378(6552):88–91. doi:10.1038/378088a0.
   PubMed Web of Science ®Google Scholar
• Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer Zum Buschenfelde KH, Neurath MF. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol. 1998;160(8):3642–3647.
   PubMed Web of Science ®Google Scholar
• Skeldon A, Saleh M. The inflammasomes: molecular effectors of host resistance against bacterial, viral, parasitic, and fungal infections. Front Microbiol. 2011;2:15. doi:10.3389/fmicb.2011.00015.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, Paul WE, Nakanishi K. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA. 1999;96(24):13962–13966. doi:10.1073/pnas.96.24.13962.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaka K, Tanaka M, Izumi S, Okamura H, Paul WE, Nakanishi K. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol. 2000;1(2):132–137. doi:10.1038/77811.
   PubMed Web of Science ®Google Scholar
• Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, Kurimoto M, Sur S. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 2000;164(5):2701–2710. doi:10.4049/jimmunol.164.5.2701.
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Matsumoto H, Ohshima N, Tashimo H, Asari I, Tajiri T, Niimi A, Nagase H, Matsui H, Kobayashi N, et al. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab. Respir Med. 2018;134:95–102. doi:10.1016/j.rmed.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987;136(1):225–244. doi:10.1164/ajrccm/136.1.225.
   PubMed Web of Science ®Google Scholar
• Ito R, Gon Y, Nunomura S, Atsuta R, Harada N, Hattori T, Maruoka S, Okayama Y, Ra C, Hashimoto S. Development of assay for determining free IgE levels in serum from patients treated with omalizumab. Allergol Int. 2014;63 (Suppl 1):37–47. doi:10.2332/allergolint.13-OA-0643.
   PubMedGoogle Scholar
• Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14(6):334–342. doi:10.1006/cyto.2001.0914.
   PubMed Web of Science ®Google Scholar
• American Thoracic S, European Respiratory S. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Miyazaki N, Oashi K, Teramoto S, Shiratori M, Hashimoto M, Ohmichi M, Abe S. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol. 2001;107(2):331–336. doi:10.1067/mai.2001.112275.
   PubMed Web of Science ®Google Scholar
• Oda H, Kawayama T, Imaoka H, Sakazaki Y, Kaku Y, Okamoto M, Kitasato Y, Edakuni N, Takenaka S, Yoshida M, et al. Interleukin-18 expression, CD8(+) T cells, and eosinophils in lungs of nonsmokers with fatal asthma. Ann Allergy Asthma Immunol. 2014;112(1):23–28 e1. doi:10.1016/j.anai.2013.09.004.
   PubMed Web of Science ®Google Scholar
• Xu D, Chan WL, Leung BP, Hunter D, Schulz K, Carter RW, McInnes IB, Robinson JH, Liew FY. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med. 1998;188(8):1485–1492. doi:10.1084/jem.188.8.1485.
   PubMed Web of Science ®Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102. doi:10.1038/nri2691.
   PubMed Web of Science ®Google Scholar
• Ando M, Shima M. Serum interleukins 12 and 18 and immunoglobulin E concentrations and allergic symptoms in Japanese schoolchildren. J Invest Allergol Clin Immunol. 2007;17(1):14–19.
   PubMed Web of Science ®Google Scholar
• Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, Ekerbicer HC. The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis. Mediat Inflamm. 2006;2006(4):1–4. doi:10.1155/MI/2006/73098.
   Google Scholar
• Sanders NL, Mishra A. Role of interleukin-18 in the pathophysiology of allergic diseases. Cytokine Growth Factor Rev. 2016;32:31–39. doi:10.1016/j.cytogfr.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Trzeciak M, Gleń J, Bandurski T, Sokołowska-Wojdyło M, Wilkowska A, Roszkiewicz J. Relationship between serum levels of interleukin-18, IgE and disease severity in patients with atopic dermatitis. Clin Exp Dermatol. 2011;36(7):728–732. doi:10.1111/j.1365-2230.2011.04113.x.
   PubMed Web of Science ®Google Scholar
• Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab. 2002;87(8):3864–3866. doi:10.1210/jcem.87.8.8781.
   PubMed Web of Science ®Google Scholar
• Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. ATVB. 2005;25(6):1268–1273. doi:10.1161/01.ATV.0000163843.70369.12.
   Google Scholar
• Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179–188. doi:10.1038/nm.2279.
   PubMed Web of Science ®Google Scholar
• Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG, Arron JR. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016;193(9):949–956. doi:10.1164/rccm.201510-2032PP.
   PubMed Web of Science ®Google Scholar
• Caswell-Smith R, Periostin Study Team, Hosking A, Cripps T, Holweg C, Matthews J, Holliday M, Maillot C, Fingleton J, Weatherall M, Braithwaite I, Beasley R. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease. Clin Exp Allergy. 2016;46(10):1303–1314. doi:10.1111/cea.12763.
   PubMed Web of Science ®Google Scholar
• James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, Ohta S, Ek A, Middelveld R, Dahlen B, et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy. 2017;72(11):1753–1760. doi:10.1111/all.13181.
   PubMed Web of Science ®Google Scholar
• Kimura H, Konno S, Makita H, Taniguchi N, Kimura H, Goudarzi H, Shimizu K, Suzuki M, Shijubo N, Shigehara K, et al. Serum periostin is associated with body mass index and allergic rhinitis in healthy and asthmatic subjects. Allergol Int. 2018;67(3):357–363. doi:10.1016/j.alit.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Shirai T, Hirai K, Gon Y, Maruoka S, Mizumura K, Hikichi M, Holweg C, Itoh K, Inoue H, Hashimoto S. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract. 2019;7(1):134–145 e1. doi:10.1016/j.jaip.2018.06.015.
   PubMed Web of Science ®Google Scholar
• Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg. 2009;19(11):1557–1563. doi:10.1007/s11695-009-9917-4.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–1154. doi:10.1016/j.jaci.2003.10.003.
   PubMed Web of Science ®Google Scholar
• Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, Liu MC. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010;125(4):896–901 e6. doi:10.1016/j.jaci.2009.10.021.
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011;72(2):306–320. doi:10.1111/j.1365-2125.2011.03962.x.
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61–76. doi:10.1111/j.1365-2125.2009.03401.x.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Glanville N, Trujillo-Torralbo MB, Shamji BW, Del-Rosario J, Mallia P, Edwards MJ, Walton RP, Edwards MR, Johnston SL. Interleukin-18 is associated with protection against rhinovirus-induced colds and asthma exacerbations. Clin Infect Dis. 2015;60(10):1528–1531. doi:10.1093/cid/civ062.
   PubMed Web of Science ®Google Scholar
• Rovina N, Dima E, Bakakos P, Tseliou E, Kontogianni K, Papiris S, Koutsoukou A, Koulouris NG, Loukides S. Low interleukin (IL)-18 levels in sputum supernatants of patients with severe refractory asthma. Respir Med. 2015;109(5):580–587. doi:10.1016/j.rmed.2015.03.002.
   PubMed Web of Science ®Google Scholar
• Alam R, Good J, Rollins D, Verma M, Chu H, Pham TH, Martin RJ. Airway and serum biochemical correlates of refractory neutrophilic asthma. J Allergy Clin Immunol. 2017;140(4):1004–1014.e13. doi:10.1016/j.jaci.2016.12.963.
   PubMed Web of Science ®Google Scholar
• Peters MC, Fahy JV. Metabolic consequences of obesity as an “outside in” mechanism of disease severity in asthma. Eur Respir J. 2016;48(2):291–293. doi:10.1183/13993003.01132-2016.
   PubMed Web of Science ®Google Scholar